Breaking News Instant updates and real-time market news.

ABCD

Cambium Learning

$12.05

0.27 (2.29%)

, TNDM

TNDM

09:12
10/15/18
10/15
09:12
10/15/18
09:12

Fly Intel: Pre-market Movers

HIGHER: Cambium Learning (ABCD), up 19% announcing it will be acquired by Veritas Capital... Tandem Diabetics (TNDM), up 4% after after receiving Health Canada approval to market t:slim X2 insulin pump... AcelRx (ACRX), up 23% after an FDA advisory committee recommended approval of Dsuvia... Harris (HRS) and L3 Technologies (LLL), up 5% and 6%, respectively, after agreeing to combine in an all stock merger of equals. UP AFTER EARNINGS: Bank of America (BAC), up 1%. LOWER: Progenics (PGNX), down 3% after filing a $250M mixed securities shelf... Axon (AAXN), down 3% after Ladenburg Thalmann analyst Glenn Mattson downgraded the stock to Neutral... Nutrisystem (NTRI), down 4% after the stock was downgraded to Underperform at DA Davidson.

ABCD

Cambium Learning

$12.05

0.27 (2.29%)

TNDM

TNDM

ACRX

AcelRx

$3.95

(0.00%)

HRS

Harris

$154.88

0.61 (0.40%)

LLL

L3 Technologies

$195.99

0.74 (0.38%)

PGNX

Progenics

$5.55

-0.035 (-0.63%)

BAC

Bank of America

$28.42

0.07 (0.25%)

AAXN

Axon

$58.91

2.7 (4.80%)

NTRI

Nutrisystem

$37.12

1.11 (3.08%)

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 24

    Oct

  • 29

    Oct

  • 03

    Nov

  • 27

    Nov

ABCD Cambium Learning
$12.05

0.27 (2.29%)

03/28/18
RILY
03/28/18
INITIATION
Target $12.5
RILY
Buy
Cambium Learning initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Kevin Li started Cambium Learning with a Buy rating and $12.50 price target. The analyst is positive on the company's transition from print to digital.
04/23/18
RILY
04/23/18
NO CHANGE
Target $12.5
RILY
Buy
Cambium Learning selloff Friday brings buying opportunity, says B. Riley FBR
B. Riley FBR analyst Kevin Liu believes the selloff Friday in shares of Cambium Learning Group creates a buying opportunity. The company told Bloomberg Friday afternoon that it is not aware of the reason for the stock drop. Liu reiterates a Buy rating on Cambium with a $12.50 price target. The stock closed Friday down 24% to $10.30.
TNDM TNDM

10/15/18
LSCM
10/15/18
NO CHANGE
Target $60
LSCM
Buy
Tandem Diabetes reimbursement from Canada is 'excellent,' says Lake Street
Lake Street analyst Brooks O'Neil views news that Tandem Diabetes has received a Health Canada Medical Device License for its t:slim X2 Insulin Pump as "excellent." The Canadian opportunity is two-times the size of the other near-term new International markets combined and it is roughly four-times the size of Tandem's entire installed base in the U.S., O'Neil tells investors in a research note. The analyst adds that Tandem shares have corrected 41.5% in the past five weeks "with no meaningful negative news." He affirms a Buy rating on the shares with a $60 price target.
09/26/18
CHLM
09/26/18
NO CHANGE
Target $59
CHLM
Buy
Tandem Diabetes price target raised to $59 from $52 at Craig-Hallum
Craig-Hallum analyst Alexander Nowak raised his price target for Tandem Diabetes to $59 from $52 after a "strong" investor event where the company beat Q3 sales estimates, raised 2018 guidance and announced solid long-term financial figures. Nowak argues that the analyst day confirms his thesis that the company with the best automation and most discreet pump will win, leading to market share gains and accelerated pump therapy penetration. He believes Tandem's story has just begun and is poised to morph into a much larger company as it executes on making diabetes therapy invisible. The analyst reiterates a Buy rating on the shares.
09/26/18
PIPR
09/26/18
NO CHANGE
Target $56
PIPR
Overweight
Tandem Diabetes price target raised to $56 from $32 at Piper Jaffray
Piper Jaffray analyst JP McKim raised his price target for Tandem Diabetes to $56 following the company's "positive" analyst day. The analyst has confidence in above average growth over the next 12 months and sees "lots of room" for estimates to go higher. The shares need to be owned during this "Goldilocks Period" where the company has the best closed loop system on the market, McKim tells investors in a research note. He reiterates an Overweight rating on Tandem Diabetes.
09/25/18
BARD
09/25/18
NO CHANGE
Target $47
BARD
Neutral
Baird not surprised by upside pre-announcement from Tandem Diabetes
After Tandem Diabetes pre-announced better than expected Q3 revenue and an updated full-year view that implies Q4 revenue largely in line with consensus estimates, Baird analyst Jeff Johnson said he was not surprised by the upside and expects the company's solid fundamentals to persist as U.S. growth remains strong and international revenue starts to contribute. However, he thinks the current valuation reflects this strength and maintains a Neutral rating and $47 price target on Tandem Diabetes shares.
ACRX AcelRx
$3.95

(0.00%)

10/10/18
HCWC
10/10/18
NO CHANGE
Target $7
HCWC
Buy
AcelRx briefing docs bode well for positive panel, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce believes the briefing document released this morning for the October 12 FDA meeting to review the resubmitted new drug application of Dsuvia bode well for a positive panel vote. The statements and tone of the FDA reviewers are broadly supportive of approval, Arce tells investors in a research note. The analyst affirms a Buy rating on AcelRx Pharmaceuticals with a $7 price target.
10/10/18
LTCO
10/10/18
NO CHANGE
Target $10
LTCO
Buy
Ladenburg says briefing docs support Dsuvia approval, ups AcelRx target to $10
After the FDA released briefing documents ahead of Friday's Advisory Committee meeting for AcelRx, Ladenburg analyst Michael Higgins said the documents "could not be more supportive of Dsuvia." He believes pre-market weakness in the shares occurred as investors initially read the comments from the prior review, which had produced a CRL, but the documents are actually "very positive on Dsuvia," he contends. Higgins, who expects the committee to vote in support of Dsuvia's efficacy, safety, proposed REMS and overall approval, raised his price target on AcelRx shares to $10 from $7 and keeps a Buy rating on the shares.
10/15/18
CANT
10/15/18
NO CHANGE
Target $8
CANT
Overweight
AcelRx price target raised to $8 from $6 at Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folkes raised his price target for AcelRx to $8 citing increased conviction that Dsuvia will be approved by the FDA on its November 3 action date following Friday's positive panel vote. AcelRx could have two product approvals within the next 12 months, along with the potential to launch or partner Dsuvia in Europe after approval earlier this year, Folkes tells investors in a research note. He believes upward earnings revisions will drive upside momentum in the stock and reiterates an Overweight rating on the name.
10/15/18
JEFF
10/15/18
UPGRADE
Target $8
JEFF
Buy
AcelRx upgraded to Buy from Hold at Jefferies
Jefferies analyst Roger Song upgraded AcelRx upgraded AcelRx Pharmaceuticals to Buy and raised his price target for the shares to $8 from $3. The analyst sees a high chance of approval for Dsuvia following Friday's positive FDA panel vote.
HRS Harris
$154.88

0.61 (0.40%)

10/15/18
FBCO
10/15/18
NO CHANGE
Target $209
FBCO
Outperform
Harris price target raised to $209 from $190 at Credit Suisse
Credit Suisse analyst Robert Spingarn raised his price target for Harris (HRS) to $209 from $190 after the company and L3 Technologies (LLL) announced an all-stock merger of equals. The analyst believes this could be "the most strategically significant and shareholder friendly" M&A deal announced since the start of the current A&D consolidation wave. He reiterates an Outperform rating on Harris' shares.
10/15/18
COWN
10/15/18
NO CHANGE
Target $180
COWN
Outperform
L3 Technologies, Harris merger likely to be a winner, says Cowen
Cowen analysts Gautam Khanna and Cai Von Rumohr said the proposed merger between L3 Technologies (LLL) and Harris (HRS) looks like a very good fit with above average cost synergy potential. They believe the deal is likely to be a winner and although there are areas of overlap they do not believe it will be a problem. Von Rumohr reiterated his Outperform rating on L3 Technologies and Khanna reiterated his Outperform rating on Harris Corp. shares.
10/15/18
FBCO
10/15/18
NO CHANGE
Target $272
FBCO
Outperform
L3 Technologies price target raised to $272 from $238 at Credit Suisse
Credit Suisse analyst Robert Spingarn raised his price target for L3 Technologies (LLL) to $272 from $238 after the company and Harris (HRS) announced an all-stock merger of equals. Though some may read into Harris buying L3 Technologies, the analyst sees this as a true merger of equals. He reiterates an Outperform rating on L3 Technologies' shares.
10/15/18
JEFF
10/15/18
NO CHANGE
Target $184
JEFF
Buy
Harris, L3 should trade up 5% on merger deal, says Jefferies
Jefferies analyst Sheila Kahyaoglu believes both Harris (HRS) and L3 Technologies (LLL) should trade up 5% following the announced merger of equals. The analyst bases this on the combined company's $3B of free cash flow generation in 2022and a 6.5% free cash flow yield, discounted back. She has a Buy rating on Harris and Hold rating on L3. Harris in premarket trading is up 5.4% to $163.25 while L3 is up 6.7% to $208.89.
LLL L3 Technologies
$195.99

0.74 (0.38%)

PGNX Progenics
$5.55

-0.035 (-0.63%)

09/13/18
NEED
09/13/18
DOWNGRADE
NEED
Buy
Progenics downgraded to Buy from Strong Buy at Needham
07/31/18
NEED
07/31/18
NO CHANGE
Target $16
NEED
Strong Buy
Progenics price target raised to $16 from $14 at Needham
Needham analyst Chad Messer raised his price target on Progenics to $16 after the FDA approved Azedra for intravenous use for certain types of locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. Messer keeps a Strong Buy rating on Progenics shares.
03/23/18
NEED
03/23/18
NO CHANGE
Target $14
NEED
Strong Buy
Needham still confident in Progenics approval despite PDUFA delay
The three month extension to Progenics' FDA action date is not related to the efficacy or safety data for Azdera, Needham analyst Chad Messer tells investors in a research note. The analyst remains confident in the drug's approval. He maintains a Strong Buy rating on the shares with a $14 price target.
09/13/18
09/13/18
DOWNGRADE
Target $12

Buy
Progenics downgraded to Buy on Phase III trial disappointment at Needham
As previously reported, Needham analyst Chad Messer downgraded Progenics to Buy from Strong Buy after its Phase III study of PSMA imaging agent 1404 in prostate cancer missed its co-primary sensitivity endpoint. Although the study did meet the specificity endpoint, the analyst believes these results fall short of expectations set based on strong Phase II results. Additionally, Messer notes that the limitations of 1404 are likely due to the SPECT/CT platform and sees no read through to PyL, Progenic's other PSMA based imaging agent that works on the more sensitive PET imaging platform. The analyst also lowered his price target on the shares to $12 from $16.
BAC Bank of America
$28.42

0.07 (0.25%)

07/09/18
GSCO
07/09/18
NO CHANGE
GSCO
Bank of America, Morgan Stanley top ideas into Q2 earnings season, says Goldman Sachs
Goldman Sachs analyst Richard Ramsden expects Bank of America (BAC) and Morgan Stanley (MS) to beat consensus estimates in Q2. The analyst argues that both appear best positioned, while he sees risk for U.S. Bancorp (USB) and JPMorgan (JPM). Ramsden highlights Bank of America given the material valuation dislocation that looks to support the stock over time. Additionally, the analyst expects an expense and NII beat for Morgan Stanley.
07/17/18
BARD
07/17/18
NO CHANGE
Target $30
BARD
Neutral
Baird would be buyers of Bank of America on weakness
Baird analyst David George said he would remain a buyer of Bank of America shares on any weakness, stating that its operating leverage was impressive in Q2 and should continue along with solid execution. George maintained his Neutral rating and $30 price target on Bank of America shares.
09/19/18
OPCO
09/19/18
NO CHANGE
OPCO
Outperform
U.S. banks 'in very good shape,' says Oppenheimer, favorites include BofA, Citi
Oppenheimer analyst Chris Kotowski tells investors in a research note that the U.S. banking group is on solid footing with balance sheets less risky than at any time over the last 33 years the firm covered the group and says his favorite bank stocks are Outperform-rated Bank of America (BAC), Citi (C), CIT (CIT) and Goldman Sachs (GS). However, Kotowski notes that banks are trading at an average relative P/E of just ~66% relative to the S&P 500 and returning to a historical avg valuation of 73%-80% range would imply over a thousand basis points of outperformance by the group. In his view, the U.S. banks are, on the whole, in "very good" shape.
09/25/18
WOLF
09/25/18
INITIATION
Target $40
WOLF
Outperform
Bank of America initiated with an Outperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated Bank of America with an Outperform and $40 price target.
AAXN Axon
$58.91

2.7 (4.80%)

09/14/18
RAJA
09/14/18
INITIATION
Target $79
RAJA
Outperform
Axon initiated with an Outperform at Raymond James
Raymond James initiated Axon with an Outperform and $79 price target.
10/08/18
BARD
10/08/18
NO CHANGE
Target $69
BARD
Neutral
Axon product launch in mid-2019 may reduce current sales, says Baird
After attending law enforcement conference IACP this weekend, Baird analyst William Power remains positive on Axon Enterprise's Taser upgrade opportunity. The company this weekend unveiled a major new Taser and body camera and announced bundled pricing that effectively includes the highly anticipated RMS software product for free on a promotional basis, Power tells investors in a research note. The analyst, however, wonders if the mid-2019 launch timeline for the new body camera could reduce current camera sales. Power keeps a Neutral rating on Axon with a $69 price target citing valuation.
10/15/18
LTCO
10/15/18
DOWNGRADE
LTCO
Neutral
Axon downgraded to Neutral from Buy at Ladenburg
Ladenburg Thalmann analyst Glenn Mattson downgraded Axon Enterprise to Neutral.
10/02/18
BARD
10/02/18
NO CHANGE
Target $69
BARD
Neutral
Baird calls new Taser from Axon a 'significant positive'
Axon Enterprise earlier today announced that it will unveil a new Taser and body camera at the IACP conference this weekend, Baird analyst William Power tells investors in a research note titled "New Taser a Significant Positive." The analyst believes a next generation Taser is likely to reinvigorate growth as the last Taser was announced over five years ago. Further, the analyst is also positive on the body camera release. However, Power keeps a Neutral rating on Axon with a $69 price target. The stock in late morning trading is down 2.5%, or $1.65, to $65.19.
NTRI Nutrisystem
$37.12

1.11 (3.08%)

10/15/18
DADA
10/15/18
DOWNGRADE
Target $28
DADA
Underperform
Nutrisystem downgraded to Underperform at DA Davidson on continued discounting
As reported earlier, DA Davidson analyst Linda Bolton Weiser downgraded Nutrisystem to Underperform from Neutral and also lowered her price target to $28 from $40. The analyst says she is less confident in the company being able to achieve the over 30% growth in Q4 EBITDA implied by its guidance and believes that the management could cut its outlook, citing "anecdotal evidence" that "steep" price discounting of as high as 29% may be continuing for Nutrisystem's reactivation customers. Weiser further notes her concern over "deteriorating Google search trends for South Beach" while also lowering her FY18 EPS view to $1.99 from $2.06.
09/14/18
DADA
09/14/18
NO CHANGE
DADA
Neutral
Nutrisystem more likely than public peers to buy Jenny Craig, says DA Davidson
After The Wall Street Journal recently reported that private equity firm North Castle Partners is seeking a buyer of Jenny Craig, DA Davidson analyst Linda Bolton Weiser said she sees "zero probability" that Medifast (MED) would acquire it and "almost zero probability" that Weight Watchers (WTW) would buy the company. Nutrisystem (NTRI), however, has already shown an interest in adding non-cannibalizing brands to its portfolio, making it the most likely buyer of Jenny Craig among the publicly-traded weight loss companies Weiser covers, she stated. Nutrisystem, which seems to have hit a wall in growing its biggest brand, may need a bold strategic move to provide visibility on growth and expansion, added the analyst. She keeps Buy ratings on Medifast and Weight Watchers and a Neutral rating on Nutrisystem shares.
07/31/18
DADA
07/31/18
DOWNGRADE
Target $40
DADA
Neutral
Nutrisystem downgraded to Neutral at DA Davidson on valuation
As reported earlier, DA Davidson analyst Linda Bolton Weiser downgraded Nutrisystem to Neutral from Buy and lowered her price target to $40 from $45. The analyst notes that she is optimistic that the company's execution can improve in the 2019 diet season, but cautions that the stock is entering a period of seasonal weakness from late summer through Q1, having already run up 43% from its March 29th lows. Weiser believes that Nutrisystem valuation may not improve until the results of the 2019 diet season are available, also lowering her PE multiple target to 15-times from 18-times.
10/15/18
DADA
10/15/18
DOWNGRADE
DADA
Underperform
Nutrisystem downgraded to Underperform from Neutral at DA Davidson

TODAY'S FREE FLY STORIES

03:05
10/14/19
10/14
03:05
10/14/19
03:05
General news
Asian Market Update: »

Asian Market Update:…

03:05
10/14/19
10/14
03:05
10/14/19
03:05
General news
FX Update: Currencies have opened the week in undramatic fashion »

FX Update: Currencies…

XLNX

Xilinx

$96.18

3.4 (3.66%)

, INTC

Intel

$52.06

0.95 (1.86%)

20:45
10/13/19
10/13
20:45
10/13/19
20:45
Upgrade
Xilinx, Intel rating change at Nomura Instinet »

Xilinx upgraded to Buy…

XLNX

Xilinx

$96.18

3.4 (3.66%)

INTC

Intel

$52.06

0.95 (1.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 20

    Nov

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

19:49
10/13/19
10/13
19:49
10/13/19
19:49
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

FB

Facebook

$184.20

4.02 (2.23%)

BBBY

Bed Bath & Beyond

$12.98

0.89 (7.36%)

AMZN

Amazon.com

$1,730.79

11.115 (0.65%)

TGT

Target

$111.86

1.29 (1.17%)

T

AT&T

$37.58

0.17 (0.45%)

ITW

Illinois Tool Works

$154.56

4.68 (3.12%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

NUE

Nucor

$52.69

2.48 (4.94%)

PNR

Pentair

$37.33

1.215 (3.36%)

GWW

Grainger

$305.24

16.49 (5.71%)

K

Kellogg

$62.14

-0.27 (-0.43%)

ATVI

Activision Blizzard

$54.80

1.1 (2.05%)

TTWO

Take-Two

$122.42

0.02 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 18

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 13

    Nov

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

IGMS

IGM Biosciences

$17.53

-0.125 (-0.71%)

19:42
10/13/19
10/13
19:42
10/13/19
19:42
Initiation
IGM Biosciences initiated at Piper Jaffray »

IGM Biosciences initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMAT

LeMaitre

$31.29

-0.03 (-0.10%)

19:37
10/13/19
10/13
19:37
10/13/19
19:37
Hot Stocks
LeMaitre acquires biologic patch business from Admedus »

LeMaitre Vascular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

18:37
10/13/19
10/13
18:37
10/13/19
18:37
Periodicals
SoftBank seeking control of WeWork through financing package, WSJ says »

SoftBank (SFTBY) has…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KOD

Kodiak Sciences

$18.24

1.34 (7.93%)

18:34
10/13/19
10/13
18:34
10/13/19
18:34
Hot Stocks
Kodiak Sciences announces safety, efficacy from Phase 1b study of KSI-301 »

Kodiak Sciences announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADVM

Adverum Biotechnologies

$5.29

0.11 (2.12%)

18:29
10/13/19
10/13
18:29
10/13/19
18:29
Recommendations
Adverum Biotechnologies analyst commentary at Piper Jaffray »

Adverum '022 looking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADVM

Adverum Biotechnologies

$5.29

0.11 (2.12%)

18:23
10/13/19
10/13
18:23
10/13/19
18:23
Hot Stocks
Adverum Biotechnologies reports additional data from Phase 1 trial of ADVM-022 »

Adverum Biotechnologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COP

ConocoPhillips

$56.41

0.55 (0.98%)

18:03
10/13/19
10/13
18:03
10/13/19
18:03
Hot Stocks
ConocoPhillips announces $1.39B agreement to sell interests in Australia-West »

ConocoPhillips announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

T

AT&T

$37.58

0.17 (0.45%)

, CMCSA

Comcast

$45.53

1.02 (2.29%)

17:18
10/13/19
10/13
17:18
10/13/19
17:18
On The Fly
Box Office Battle: 'Joker' stays at number 1 with another $55M »

"Box Office Battle" is…

T

AT&T

$37.58

0.17 (0.45%)

CMCSA

Comcast

$45.53

1.02 (2.29%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$58.16

0.83 (1.45%)

LGF.A

Lionsgate

$9.52

0.22 (2.37%)

LGF.B

Lionsgate

$8.97

0.19 (2.16%)

DIS

Disney

$130.08

0.73 (0.56%)

VIAB

Viacom

$23.02

0.505 (2.24%)

VIA

Viacom

$25.45

0.65 (2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 14

    Nov

  • 14

    Nov

  • 19

    Nov

PCG

PG&E

$8.08

0.3 (3.86%)

16:48
10/13/19
10/13
16:48
10/13/19
16:48
Periodicals
PG&E turns down San Francisco's $2.5B offer to acquire assets, Reuters says »

PG&E rejected a $2.5B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 07

    Jan

TTGT

TechTarget

$22.64

0.14 (0.62%)

, SKHCY

Sonic Healthcare

$0.00

(0.00%)

16:44
10/13/19
10/13
16:44
10/13/19
16:44
Conference/Events
Commvault to hold a conference »

Commvault GO 2019 will be…

TTGT

TechTarget

$22.64

0.14 (0.62%)

SKHCY

Sonic Healthcare

$0.00

(0.00%)

NTAP

NetApp

$51.50

1.74 (3.50%)

HPE

HP Enterprise

$14.35

0.24 (1.70%)

HLF

Herbalife Nutrition

$39.07

0.51 (1.32%)

FORR

Forrester

$32.43

0.61 (1.92%)

CSCO

Cisco

$46.52

0.38 (0.82%)

CVLT

Commvault

$45.51

0.695 (1.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 23

    Oct

  • 29

    Oct

  • 29

    Oct

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

  • 12

    Dec

FB

Facebook

$184.20

4.02 (2.23%)

16:43
10/13/19
10/13
16:43
10/13/19
16:43
Periodicals
Warren buying Facebook ads claiming Zuckerberg backs Trump, Bloomberg says »

Elizabeth Warren is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 30

    Oct

KBH

KB Home

$33.92

-0.15 (-0.44%)

16:43
10/13/19
10/13
16:43
10/13/19
16:43
Conference/Events
SunTrust to hold a field trip »

Field Trip with KB Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Oct

BX

Blackstone

$47.10

0.62 (1.33%)

16:34
10/13/19
10/13
16:34
10/13/19
16:34
Periodicals
Blackstone discussed with Citadel about buying stake, WSJ reports »

Blackstone has held talks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

, GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

16:29
10/13/19
10/13
16:29
10/13/19
16:29
Periodicals
Google bars high-interest consumer loan services from app store, WSJ reports »

Google has barred…

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$296.34

3.1 (1.06%)

16:28
10/13/19
10/13
16:28
10/13/19
16:28
General news
Trump working with Congress on 'powerful' Turkey sanctions »

President Trump tweeted…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$296.34

3.1 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$169.06

1.255 (0.75%)

16:23
10/13/19
10/13
16:23
10/13/19
16:23
Hot Stocks
Allergan, Molecular Partners present data from Phase 3 Abicipar pegol studies »

Allergan and Molecular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYFT

Lyft

$39.49

1.8 (4.78%)

, UBER

Uber

$30.09

1.19 (4.12%)

16:04
10/13/19
10/13
16:04
10/13/19
16:04
Periodicals
Lyft sues NYC over cruising time caps, Reuters reports »

Following its rival…

LYFT

Lyft

$39.49

1.8 (4.78%)

UBER

Uber

$30.09

1.19 (4.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 04

    Nov

  • 07

    Nov

  • 19

    Nov

GM

General Motors

$35.57

0.9 (2.60%)

15:59
10/13/19
10/13
15:59
10/13/19
15:59
Periodicals
UAW boosting strike pay as General Motor walkout continues, Reuters says »

The United Auto Workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MRK

Merck

$84.31

0.6 (0.72%)

, JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

15:49
10/13/19
10/13
15:49
10/13/19
15:49
Periodicals
Congo to start using Johnson & Johnson Ebola vaccine next month, Reuters says »

Health authorities in…

MRK

Merck

$84.31

0.6 (0.72%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 23

    Oct

  • 29

    Oct

  • 06

    Nov

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

HMTV

Hemisphere Media

$11.70

0.05 (0.43%)

15:48
10/13/19
10/13
15:48
10/13/19
15:48
Initiation
Hemisphere Media initiated at Wells Fargo »

Hemisphere Media…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$36.11

0.31 (0.87%)

15:37
10/13/19
10/13
15:37
10/13/19
15:37
Hot Stocks
Pfizer presents Phase 3 data for Abrocitinib in moderate to severe AD »

Pfizer announced complete…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.